The organization has given 29 research grants to scientists representing 17 different US institutions pursuing lymphoma treatments and cures in their work.
Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
